Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

The Icelandic genomics company DeCode announced details of its rebirth yesterday, most notably dropping its drug development efforts. The company, which has churned out a huge body of genetic research in the last decade–much of it published in high profile scientific journals–filed for chapter 11 bankruptcy protection in the U.S late last year. The company has spent more than $600 million but never turned a profit.

Decode began as a sort of national genomics effort, capitalizing on Iceland’s self-contained population, well-documented genealogies, and openness to genetic research to search for genes linked to different diseases. (In the early days, these characteristics allowed scientists to pinpoint these genes more easily than in a general population.) As genomics technology advanced, the company moved to whole genome association studies, identifying genes linked to heart disease, stroke, skin cancer and schizophrenia. In the process, DeCode generated a massive genomics database, as well as expertise in collecting and analyzing huge volumes of data, which it now hopes to capitalize on. Rather than trying to develop drugs on its own, the company plans to partner with pharmaceutical firms.

The company will continue to offer its consumer genetic-testing website, deCodeME, launched in 2007.

According to the New York Times,

The new DeCode is owned by Saga Investments, an alliance that includes two leading life science investment companies, Polaris Ventures and ARCH Venture Partners. Terrance McGuire, a general partner at Polaris, said DeCode had been recapitalized because its research and database, formed from the medical records of the Icelandic population, were a valuable asset. “From an investor’s perspective, it was the power of the content being created,” he said.

…Dr. Stefansson said that the company’s genetic research in Iceland would carry on just as before and that DeCode would “continue to outperform” its mostly university-based rivals in the United States and England. The commercial operation will be lead by Mr. Collier in the United States, Dr. Stefansson said.

For more of TR’s coverage of DeCode, check out this Q&A with Kari Stefansson from 2006, which highlights the company’s high hopes for drug development. And this feature describing its early efforts.

0 comments about this story. Start the discussion »

Tagged: Biomedicine, genomics, decode, iceland

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me